DPA.F · Daito Pharmaceutical Co.,Ltd

-

Please sign in to comment on DPA.F

1 Comment

Admin

4 years ago

Daito Pharmaceutical Co.,Ltd is currently in a long term uptrend where the price is trading 10.7% above its 200 day moving average.

From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.0.

Daito Pharmaceutical Co.,Ltd's total revenue rose by 6.4% to $12B since the same quarter in the previous year.

Its net income has increased by 1.8% to $1B since the same quarter in the previous year.

Based on the above factors, Daito Pharmaceutical Co.,Ltd gets an overall score of 4/5.

ISIN	None
Exchange	F
CurrencyCode	EUR
Sector
Industry

Market Cap	358M
PE Ratio	10.64
Target Price	None
Dividend Yield	1.5%
Beta	0.48

ABOUT

Daito Pharmaceutical Co.,Ltd

Daito Pharmaceutical Co.,Ltd. manufactures and sells pharmaceutical products worldwide. The company offers various active pharmaceutical ingredients and intermediates, prescription drugs, OTC drugs, and home-delivery medicines; formulations in various forms, such as tablets, capsules, troches, granules, and powders; and contract manufacturing services for formulations of medicinal products to pharmaceutical companies. It also sells health food products. The company was formerly known as Daito Corporation and changed its name to Daito Pharmaceutical Co.,Ltd. in 1992. Daito Pharmaceutical Co.,Ltd. was incorporated in 1942 and is headquartered in Toyama, Japan.

DPA.F · Daito Pharmaceutical Co.,Ltd

-

Daito Pharmaceutical Co.,Ltd

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Daito Pharmaceutical Co.,Ltd using a moving average strategy